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Abstract
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and  
IGF-1. Aryl hydrocarbon receptor interacting protein (AIP) mutations are associated with 
an aggressive, inheritable form of acromegaly that responds poorly to SST2-specific 
somatostatin analogs (SSA). The role of pasireotide, an SSA with affinity for multiple  
SSTs, in patients with AIP mutations has not been reported. We studied two AIP mutation 
positive acromegaly patients with early-onset, invasive macroadenomas and inoperable 
residues after neurosurgery. Patient 1 came from a FIPA kindred and had uncontrolled 
GH/IGF-1 throughout 10 years of octreotide/lanreotide treatment. When switched to 
pasireotide LAR, he rapidly experienced hormonal control which was associated with 
marked regression of his tumor residue. Pasireotide LAR was stopped after >10 years due  
to low IGF-1 and he maintained hormonal control without tumor regrowth for >18 months 
off pasireotide LAR. Patient 2 had a pituitary adenoma diagnosed when aged 17 that  
was not cured by surgery. Chronic pasireotide LAR therapy produced hormonal control 
and marked tumor shrinkage but control was lost when switched to octreotide. Tumor 
immunohistochemistry showed absent AIP and SST2 staining and positive SST5. Her AIP 
mutation positive sister developed a 2.5 cm follicular thyroid carcinoma aged 21 with 
tumoral loss of heterozygosity at the AIP locus and absent AIP staining. Patients 1 and 
2 required multi-modal therapy to control diabetes. On stopping pasireotide LAR after 
>10 years of treatment, Patient 1’s glucose metabolism returned to baseline levels.  
Long-term pasireotide LAR therapy can be beneficial in some AIP mutation positive 
acromegaly patients that are resistant to first-generation SSA.
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Introduction
Acromegaly is a rare, classical endocrine disorder that 
is due to chronic excess secretion of growth hormone 
(GH) and insulin-like growth factor 1 (IGF-1) that has 
a prevalence of 1 in 8000–14,000 of the population 
(1, 2, 3, 4). A somatotropinoma of the anterior pituitary 
gland is the predominant cause of acromegaly. In the 
largest international series of >3100 patients, acromegaly 
presented at a median age of 45.2 years, and was slightly 
more common in women (54.5%) (5). The pituitary 
tumors in acromegaly are generally macroadenomas 
(>10 mm in diameter), and nearly half of patients have 
local tumor invasion at diagnosis.
Many studies have examined the molecular genetic 
pathophysiology of acromegaly. The best-known 
molecular change underlying somatotropinomas are 
somatic activating mutations of GNAS that are present 
in up to 40% of tumors (6). Inheritable germline genetic 
mutations are considerably rarer and acromegaly can 
occur as part of multi-organ tumor syndromes such as 
multiple endocrine neoplasia type 1 (MEN1), McCune–
Albright Syndrome (MAS), Carney complex, and the 
emerging pheochromocytoma-paraganglioma-pituitary 
adenoma association (3PA) (7). Mutations in the aryl 
hydrocarbon receptor interacting peptide (AIP) gene 
account for the largest proportion of genetic/inheritable 
forms of acromegaly. Among unselected acromegaly 
populations, 0–4% of patients have AIP mutations/
deletions, which rises in more focused groups such as 
familial isolated pituitary adenoma (FIPA) kindreds 
and young patients, reaching nearly 30% in those with 
pituitary gigantism (8). AIP mutations confer a series of 
important aggressive characteristics in acromegaly. As 
compared with non-mutated acromegaly patients, those 
with AIP mutations have a statistically significantly 
younger age at onset, larger tumor size, and higher GH 
secretion (9, 10). Importantly, treatment of acromegaly 
in AIP-mutated patients is more difficult due to this 
aggressive disease profile; in particular those with AIP 
mutations have a significantly lower hormonal response 
to first-generation, receptor subtype 2 (SST2) specific 
somatostatin analogs (octreotide and lanreotide) and 
have a decreased rate of tumor shrinkage on treatment (9). 
The molecular mechanism for this relative somatostatin 
analog resistance may occur via Gai proteins or ZAC1, 
which are themselves important mediators of SST2 actions 
(11, 12, 13). Given the relatively poor results achieved 
with first-generation somatostatin analogs in patients 
with AIP mutations, the role of other agents such as the 
GH receptor antagonist pegvisomant has been described 
in those with AIP mutations (14). Pasireotide is a newer 
somatostatin analog that is approved for use in patients 
that are resistant to first-generation agents (15). It has a 
high affinity for multiple SSTs, including SST2, SST3 and 
SST5, which permits significantly improved control in 
those resistant to octreotide/lanreotide (16). Despite the 
well-known resistant profile of AIP mutation acromegaly 
patients, little specific information is available on the 
use of pasireotide in this distinct subgroup of aggressive 
disease. Here we discuss our long-term experience in 
two patients with different germline AIP mutations 
who were resistant to octreotide and lanreotide but 
that had hormonal control and/or tumor shrinkage on 
pasireotide therapy.
Methods
Genetic testing
Patients and their families provided informed written 
consent for genetic testing, which was performed under 
an approval of the Ethics Committee of the Centre 
Hospitalier Universitaire de Liège.
Immunohistochemistry
AIP immunostaining of paraffin preserved tumor tissue 
(pituitary in Patient 2 and thyroid cancer in the sister 
of Patient 2) was performed with a monoclonal IgG 
antibody (Novus Biological, Cambridge, UK) at dilutions of 
1:500–1:1000. Pituitary tumor tissue from surgery in 1994 
was no longer available for Patient 1. Somatostatin receptor 
immunohistochemistry was performed according to Körner 
et  al. (17). The primary antibodies were as follows: SST2 
(clone UMB-1 (SST2a isoform), dilution: 1/500), SST3 (clone 
UMB-5, dilution: 1/750), SST5 (clone UMB-4, dilution: 
1/75) were purchased from Abcam (Cambridge, MA, USA).
Patients and results
Patient 1
In 1994, a 29-year-old male patient first attended the 
ophthalmologist with discomfort in the left sub-orbital 
area and blurred vision of the left eye for several weeks. 
He also complained of numbness on the right side of his 
face, headache and fatigue. Ophthalmological evaluation 
revealed bitemporal hemianopia, more pronounced on 
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the left side. Pituitary MRI was performed showing a 
pituitary macroadenoma measuring 25 mm in its largest 
diameter, compressing the optic chiasma and invading in 
the right cavernous sinus. He was referred to our clinic 
and on examination had acral enlargement, prognathism, 
macroglossia, thickened skin, deep voice, and increased 
sweating, consistent with acromegaly. He was 175 cm in 
height and had normal growth patterns in childhood 
and adolescence; his parents were of normal height 
(Fig. 1). His body mass index was BMI 30 kg/m2 and he 
was normotensive. Laboratory tests revealed increased 
random GH (3.3 ng/mL) and IGF-1 (1116 mg/mL; normal 
range: 85–218), and hyperprolactinemia (739 mIU/L; 
Fig. 2A). Other biochemical and hormonal profiles were 
normal apart from the presence of impaired glucose 
tolerance. He underwent a transsphenoidal resection 
of the accessible pituitary tumor mass, but a sizable 
(16 mm) tumor remnant adjoining the right cavernous 
sinus could not be accessed surgically (Fig. 2B). Pathology 
studies showed a pituitary adenoma with positive 
immunostaining for GH and prolactin. Postoperatively 
the patient had deficiencies in the thyrotrope and 
gonadotrope axes and he received supplementation. 
During follow-up, Patient 1 had elevated GH/IGF-1 levels 
and he was treated with octreotide, first as a three times 
daily subcutaneous injection (Fig. 2). Over the following 
10  years, he received long-acting forms of lanreotide 
and octreotide up to the maximum doses. Clinically, the 
patient experienced partial symptomatic benefits from 
the SSA treatment but IGF-1 levels were uncontrolled. 
Addition of a dopamine agonist did not improve his 
control. His impaired glucose tolerance worsened and he 
was diagnosed with type 2 diabetes mellitus that required 
treatment with metformin. Over the following years there 
was evidence of tumor expansion during somatostatin 
analog treatment. The patient declined radiotherapy and 
reoperation and he remained uncontrolled through to 
2006; pegvisomant treatment, when it became available, 
was also declined due to the incomplete control of tumor 
size on a somatostatin analog.
In 2006 the patient discontinued first-generation 
somatostatin analogs and began pasireotide LAR 
30 mg/month as part of a research study. Following 
up-titration to 60 mg, monthly GH and IGF-1 levels 
were normalized and the patient reported improvement 
in clinical signs and symptoms of acromegaly (Fig.  2). 
Serial MRIs showed significant and continuing tumor 
shrinkage, even after pasireotide LAR dose was optimized 
at 40 mg/month (Fig.  2C). By 2013 his GH and IGF-1 
remained controlled and MRI showed an empty sella 
and a small intrasellar tumor remnant. Pasireotide LAR 
treatment was associated with worsening of existing 
diabetes. Before beginning pasireotide his HbA1c had 
been 6.2% on metformin and a thiazolidinedione, but 
rose to 8.8% on pasireotide despite various combined 
drug therapies including metformin, dipeptiyl peptidase-4 
(DPP-4) inhibitors, a sulfonylurea and GLP-1 agonists. 
HbA1c was eventually brought down to <7% with the 
Figure 1
Genealogic trees of Patient 1 and Patient 2. The 
nephew of Patient 1 who was positive for an AIP 
mutation is unaffected by pituitary or other 
diseases; deceased members in the kindred of 
Patient 1 died for reasons unrelated to pituitary 
or endocrine diseases. The AIP mutation positive 
father of Patient 2 is unaffected by pituitary or 
other endocrine conditions.
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addition of insulin glargine. With chronic treatment using 
pasireotide LAR 40 mg/month, IGF-1 levels continually 
trended downwards to below the lower limit of normal 
for age and sex. Given that the tumor remnant had also 
shrunk with pasireotide LAR, it was decided to reduce the 
pasireotide dose to bring the IGF-1 into the normal range 
again. Hence, pasireotide LAR was stopped after 11 years 
of continual treatment and anti-diabetic medication was 
reduced concomitantly. Remarkably, after more than 
18 months off pasireotide LAR, the IGF-1 has remained 
in the middle of the normal range, acromegaly symptoms 
are controlled and no tumor recurrence/regrowth has 
been seen on MRI (Fig. 2A and D). Diabetes medication 
has returned to pre-pasireotide baseline treatment with 
metformin and the last HbA1c was 7.2%; no evidence 
of cardiac disease, thyroid disease or colonic polyps was 
found on surveillance.
The family history of the patient was informative, in 
that his sister was also diagnosed with acromegaly (aged 
24 years), but she was cured after a complete resection of 
her pituitary macroadenoma (Fig. 1). The kindred formed 
part of the initial patient group that led to the proposal of 
FIPA as a disease as MEN1 and Carney complex were ruled 
out clinically/genetically. With the discovery of AIP gene 
as a pituitary adenoma predisposition gene, Patient 1 and 
his sister were found to have a c.649C>T (p.Gln217X) 
truncating mutation (18). Sequencing of all six exons 
and intronic boundaries of AIP gene was performed as 
previously described (19). Extensive family screening 
identified only one mutation carrier who remains 
asymptomatic on regular screening (including hormonal 
testing and a normal baseline MRI) >12 years later.
Patient 2
In 2008, a 16-year-old female attended her physician due 
to primary amenorrhea and weight gain. She was found 
to have hyperlipidemia and insulin resistance and dietary 
modifications were made. Menarche occurred at the age of 
17 years and thereafter she suffered from oligomenorrhea. 
Subsequent investigation revealed hyperprolactinemia 
(68 ng/mL (NR 1.9–24) ng/mL) and an 8 × 5 mm pituitary 
adenoma was identified (Fig. 3). She was diagnosed with a 
prolactinoma; cabergoline (0.5 mg/week) was started and 
normalized the prolactin, but the tumor was unchanged 
on MRI 12 months later. The patient was abroad without 
endocrine follow-up for more than a year. On her return, 
she exhibited weight gain, had grown by four centimeters 
in height (183 cm; +3.06 SDS; 20 cm over mid-parental 
height) and had headaches, amenorrhea, acromegalic 
Figure 2
Panel A shows hormonal responses over 24 years from diagnosis to last follow-up in November 2018 in Patient 1. IGF-1 and HbA1c levels are shown in 
response to octreotide/lanreotide depots and then with pasireotide LAR beginning in 2006, until withdrawn 18 months ago. The normal range for IGF-1 is 
outlined in grey in the lower part of the graph. The postoperative tumor residue is shown in panel B (arrow) and the shrinkage of the tumor in panel C 
after about five years of pasireotide therapy. Panel D shows the MRI after >12 months off all somatostatin analogs.
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features, galactorrhea and acanthosis nigricans. She had 
an elevated baseline GH of 15.7 ng/mL and an IGF-1 of 
1188 ng/mL (age-related normal range: 138–442 ng/mL); 
she had stopped cabergoline some months previously 
and her prolactin was raised at 86 ng/mL. A diagnosis of 
acromegaly was made and a repeat MRI showed a marked 
increase in her adenoma, which was now a 37 × 25 × 20 mm 
invasive macroadenoma impinging on the optic chiasm 
(Fig.  3). She was referred to a specialist pituitary center 
and a partial transsphenoidal neurosurgical resection 
was performed, which confirmed a pituitary adenoma 
(Ki-67: 3%) that was strongly positive for GH and prolactin 
and weakly FSH positive. She underwent a second 
neurosurgical intervention to further debulk her tumor.
Postoperatively, Patient 2 had residual tumor tissue 
and uncontrolled GH (7.7 ng/mL) and IGF-1 (888 ng/mL) 
levels. She underwent two acute tests, one with 
octreotide 100 μg s.c. and one with pasireotide 600 μg 
s.c. The octreotide test led to no change in GH, while 
the pasireotide test diminished GH from a baseline of 
9.5 to 3.3 ng/mL after 4 h. She was started on pasireotide 
LAR 20 mg i.m. every 4  weeks and this was up-titrated 
to 60 mg over 12  months and during this time her 
IGF-1 was normalized (203 ng/mL). Symptomatically 
the patient reported improvements. Her HbA1c before 
starting pasireotide LAR was 5.8%, and this rose (7.3%) 
during pasireotide LAR treatment and she was started on 
metformin. With continued pasireotide LAR treatment, 
HbA1c continued to rise and insulin treatment was 
instituted; over the same period IGF-1 fell below the lower 
limit of normal and a decision was made to switch to 
octreotide LAR 40 mg/month i.m. Over a 3-month period, 
IGF-1 became uncontrolled, rising from 90 to 503 ng/mL 
and HbA1c fell slightly to 6.3%. Due to this rapid 
loss of hormonal control, pasireotide LAR was restarted 
at a dose of 40 mg/month, which was up-titrated to 
60 mg/month after six months and IGF-1 was controlled 
again (235 ng/mL). Restarting pasireotide LAR was 
associated with worsening of the diabetic control and 
HbA1c rose to 11.5% and required treatment with 
metformin, dapagliflozin, extendin and gliclazide. Serial 
MRI during the period of pasireotide LAR treatment 
showed a gradual and significant reduction in the residual 
tumor size by the end of the third year of pasireotide 
LAR treatment (Fig. 3). At last follow-up after more than 
6 years of pasireotide LAR therapy, her IGF-1 was normal 
(165 ng/mL) and her tumor remnant was very small. 
Diabetes remained difficult to control (HbA1c: 9.2%) on 
multiple therapies (dulaglutide, metformin, empagliflozin 
and gliclazide); she had ongoing problems with obesity 
(bariatric surgery was planned) and a diagnosis of 
non-alcoholic steatohepatitis (NASH) was established. 
Figure 3
Trends in growth and shrinkage of the pituitary adenoma in Patient 2. A T1-weighted gadolinium-enhanced (T1Gd) MRI image of the tumor at diagnosis 
(2008) is shown by the arrow. At that time, it was a microadenoma and prolactin hypersecretion had been established. Slow progression until the 2009 
MRI is in marked contrast with the MRI in 2011, when a T2-weighted image shows a large, invasive pituitary macroadenoma had developed, in 
association with frank signs and symptoms of acromegaly and increased height. Postoperatively, a sizable residue in seen from 2012, but this shrank 
progressively when the patient was on pasireotide LAR therapy up until the 2016 and 2018 MRI images where there remains evidence of only a small 
potential tumor residue (arrow).
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Investigations of acromegaly-associated complications 
revealed colon polyposis (no malignancy), normal 
echography of the heart and no thyroid nodules.
Given the patient’s history of an early onset, invasive 
GH-secreting macroadenoma occurring in her teens, she 
was referred for genetic testing before her first surgery, 
which revealed a novel germline AIP mutation, c.343delC 
(p.(Leu115Trpfs*41)), that led to a predicted early 
truncation of the protein. The family history was positive 
for an older sister who had a 2.5 cm invasive follicular 
thyroid carcinoma diagnosed and successfully treated by 
total thyroidectomy and radioiodine at the age of 21 years 
(Fig.  1). Genetic testing in the family revealed that the 
sister with thyroid cancer was also an AIP mutation 
carrier, as was the unaffected father. Further testing of the 
pituitary tissue from Patient 2 and of the thyroid tumor 
tissue from her sister revealed loss of heterozygosity at the 
AIP locus, indicating a second hit had taken place in both 
pituitary and thyroid tumors. Immunohistochemistry 
of the follicular thyroid cancer showed no AIP staining 
(Fig. 4). Similarly, the pituitary adenoma in Patient 2 had 
low or absent AIP staining on immunohistochemistry 
(Fig. 4). Further immunostaining demonstrated that SST2 
was virtually absent throughout the pituitary tumor, 
whereas SST5 staining was positive but quite variable in 
different sampling regions of the somatotropinoma. SST3 
staining was high (Fig. 5).
Discussion
Pasireotide is a somatostatin analog with activity at 
multiple SSTs, which binds preferentially to SST5 and SST2 
(20). In the clinical setting, pasireotide is used in either 
short-acting or long-acting depot formulations for the 
treatment of Cushing’s disease and acromegaly (21, 22). 
In acromegaly, pasireotide LAR is indicated for patients 
that have failed previous therapy with SST2-specific drugs, 
such as octreotide and lanreotide. When compared with 
the SST2-specific agents, switching to pasireotide has 
been shown to improve control of acromegaly in resistant 
patients (23). Patients with germline AIP mutations are 
one of the few well-characterized forms of SST2-specific 
SSA resistance in acromegaly and such patients can have 
the dual problem of incomplete hormonal control and a 
lack of clinically meaningful pituitary tumor shrinkage (9). 
To date, however, there has been no specific information 
on the use of pasireotide LAR in treating patients 
with octreotide/lanreotide resistance due to germline 
AIP mutations.
Here, we show that long-term pasireotide LAR 
treatment can provide control of GH, IGF-1 and induce 
significant tumor shrinkage in two unrelated AIP-mutated 
acromegaly cases treated for 6–11  years. The clinical 
experience in these two cases mirrors that of good 
responders to pasireotide LAR from clinical trials. 
Insufficient hormonal control with octreotide/lanreotide 
in acromegaly can be improved by switching to 
pasireotide, as was seen in Patient 1. He was left with 
an unresectable residue postoperatively, which proved 
resistant to octreotide and lanreotide depots. In parallel 
with the hormonal control under pasireotide LAR, tumor 
shrinkage also occurred over the long term. Despite 
withdrawal of pasireotide LAR for more than 18 months, 
tumor tissue has not regrown. Given that hormonal 
control has also endured while off pasireotide LAR, it 
suggests that the residue has undergone involution. 
Patient 1 was never treated with radiotherapy, so the most 
Figure 4
AIP immunostaining in tumors from Patient 2 and family. Panel A shows normal thyroid tissue with strong positivity for AIP (brown) from the  
AIP mutation-positive sister of Patient 2 who had a 2.5 cm follicular thyroid carcinoma at a young age. In panel B the AIP staining of  
the follicular thyroid carcinoma is generally negative or scant. Panel C shows the absent or low AIP immunostaining in the somatotropinoma  
of Patient 2 at 20× and 40× resolutions.
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likely explanation currently is that chronic pasireotide 
LAR was responsible. The mechanism by which this 
involution occurred is unknown but we suggest that 
activation of SST5-predominant anti-proliferative and 
pro-apoptotic pathways as seen in corticotropes could 
also be involved in somatotropinomas with disordered 
AIP function (24, 25). Patient 2 has had a shorter duration 
of pasireotide LAR treatment overall, but as seen in Fig. 3, 
continuing treatment over 6  years led to very marked 
tumor shrinkage and long-term IGF-1 control. In both of 
the cases described here, the pasireotide-induced tumor 
shrinkage occurred in difficult to reach regions, which is a 
clinically meaningful benefit.
Unlike Patient 1 who was diagnosed in 1994, Patient 
2 was diagnosed after the role of AIP mutations in the 
etiopathology of young-onset aggressive acromegaly had 
been recognized. Patient 2 provides a rare insight into the 
natural history of the development of an AIP mutation-
positive pituitary adenoma. The first diagnosis was one of a 
microprolactinoma; the accompanying clinical symptoms 
(menstrual disturbance) and hyperprolactinemia meant 
that acromegaly was not suspected initially. Over the first 
year after diagnosis the tumor did not undergo significant 
growth and cabergoline treatment may have contributed 
to this. However, in parallel with the onset of clear 
GH/IGF-1 driven acromegalic symptoms and increased 
vertical growth, the tumor grew significantly to become 
an invasive macroadenoma. Indeed, by the time of her 
somatotropinoma diagnosis she was already well in excess 
of her mid-parental height, which suggests strongly that 
her tumor had long established GH hypersecretion. This 
snapshot of the early progression of an AIP mutation-
related pituitary adenoma suggests that tumor growth 
may not be uniform and that some other feature of the 
tumor alters behavior and growth quite rapidly. It may 
be that continued tumor proliferation is associated with 
accumulation of new genetic changes that themselves 
induce more aggressive expansion. In that setting 
AIP mutations could act as a driver mutation but also 
work in concert with other mutations or copy number 
variations to produce the final phenotype of large, 
invasive, somatostatin analog resistant pituitary 
adenomas. In line with this we previously showed that 
loss of heterozygosity – indicative of a second hit at 
the AIP locus – was a later event than hyperplasia in 
the macroadenomas of two sisters with germline AIP 
mutations (26).
At the time of diagnosis of Patient 2, it was recognized 
that resistance to first-generation somatostatin analogs 
was a characteristic of AIP mutation positive acromegaly 
Figure 5
Somatostatin receptor (SST) immunohistochemistry in the pituitary adenoma from Patient 2 and control acromegaly case. Panels A, B and C show the 
SST2, SST3 and SST5 staining in the somatotropinoma from Patient 2. Staining of two tumor samples for SST2 and SST5 are shown in panels A and C 
(surgery 1 inset; surgery 2 main picture), demonstrating negative SST2 staining and variably positive SST5 staining, predominantly membranous. SST3 
staining (panel B) was strongly positive. For comparison purposes, panels D, E and F show examples of SST2, SST3 and SST5 staining, respectively in 
tumor from a representative octreotide-responsive AIP mutation-negative adult acromegaly patient.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-19-0004
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/20/2019 10:20:12AM
via Universitaetsbibliothek Bern and Universitat Bern
A F Daly et al. Pasireotide in AIP-mutated 
acromegaly
374
PB–11
8:4
(9). Hence, the patient had test doses of subcutaneous 
pasireotide and octreotide. The role of such test dosing 
to predict responses to long-term octreotide/lanreotide 
treatment is controversial, but similar studies of 
pasireotide test dosing have not been performed widely. 
Although it is not a standard approach, when considering 
switching to pasireotide in octreotide-resistant patients, 
the use of a test dose might be informative, at least in 
AIP-mutated patients. In Patient 2, we later found no 
clinical response to a first-generation compound when 
switched from pasireotide LAR to octreotide LAR for three 
months, indicating the test dose approach was helpful in 
this case. In addition, SST immunohistochemistry showed 
absent SST2 staining and moderate membranous SST5 
staining; this further argued in favor of using pasireotide 
LAR as it is not an SST2 dependent compound. Recently 
Yamamoto et  al. reported the case of an AIP mutation-
negative acromegaly patient who had a negative 
response to an octreotide test dose (paradoxical rise in 
GH) (27). That patient had other features suggestive of 
poorer first-generation SSA responses, including tumor 
hyperintensity on T2-weighted images (28). Yamamoto 
et  al. found good tumoral and hormonal responses to 
pasireotide and subsequent surgery showed the tumor 
to be negative for AIP immunostaining and to have a 
low level of SST2 vs SST5 staining. Previous studies in 
AIP-mutated and non-mutated acromegaly cases have 
emphasized the importance of AIP immunohistochemical 
staining intensity in the responsiveness to first-generation 
somatostatin analogs (29, 30, 31, 32). Somatostatin 
analogs themselves can potentially alter AIP expression 
and actions via molecules such as ZAC1, a key factor 
in SST2-mediated effects of octreotide (12, 13, 33). 
Recently, Iacovazzo et al. reported that the only predictor 
of pasireotide responsiveness in octreotide/lanreotide-
resistant patients was the presence of SST5 (34). Should 
the molecular profile of AIP-mutated pituitary adenomas 
give rise to a greater likelihood of low AIP/SST2 protein 
expression coupled with membranous SST5, this might 
explain the relative resistance to first-generation SSA and 
argue for the specific use of pasireotide as tailored medical 
therapy for some patients with AIP mutations.
The aggressive nature of pituitary adenomas in 
those with AIP mutations raises a series of challenges 
for clinical management. As tumors are generally 
large and are often invasive at diagnosis, primary 
neurosurgical cure, as occurred in the sister of Patient 1, 
is unfortunately, the exception. Furthermore, unlike 
in acromegaly in general where it is usually helpful, 
surgical debulking in AIP mutated acromegaly cases is 
not guaranteed to increase control with postoperative SSA 
(9, 35, 36). Patients with AIP mutations also are generally 
young at disease onset, and these patients are at risk of 
increased vertical growth leading to pituitary gigantism, 
of which AIP mutations are the leading genetic cause (37). 
In pituitary gigantism, early hormonal control is associated 
with decreased final height so the instigation of effective 
therapy is key (38). Use of pegvisomant in combination 
with first-generation somatostatin analogs has proven 
effective in young AIP-mutated patients, including those 
with pituitary gigantism (14, 39).
AIP mutations are usually seen in the setting of FIPA 
or gigantism and are not known to associate with other 
non-pituitary tumor types even though AIP is a widely 
expressed protein (8). While thyroid nodules are common 
in acromegaly, coexistence of differentiated thyroid 
carcinoma in AIP-mutated acromegaly patients is very 
rare (40). The case of the follicular thyroid cancer in the 
AIP mutation-positive sister of Patient 2 is, therefore, very 
unusual. She was diagnosed with a 2.5 cm minimally 
invasive follicular thyroid carcinoma (T2N0Mx) of the 
right lobe and was cured by total thyroidectomy and 
radioactive iodine ablation at the age of 21  years. This 
carcinoma occurred at a much younger age than is typical 
for follicular thyroid cancer, which has a peak incidence 
between 40 and 60 years of age. Raitila et al. reported that 
AIP mutations do not predispose to familial non-medullary 
thyroid cancer (papillary and follicular), and a follicular 
thyroid cancer from a patient with a family history of 
AIP mutation was found not to have any disordered AIP 
immunohistochemical staining or loss of heterozygosity 
in their thyroid tumor (41). Unlike that case, the patient 
we describe had decreased AIP staining in the tumor 
tissue as compared with her own normal thyroid gland, 
and there was evidence of loss of heterozygosity at the 
AIP locus in the tumor DNA. It is, however, important, 
to note that follicular thyroid cancers frequently (up to 
14%) have genomic loss at chromosome 11q13, so the 
role of the AIP mutation as an initiating event is open to 
question (42, 43). Further studies of AIP expression and 
AIP genetic status among follicular thyroid cancer cohorts 
might be warranted.
As expected in acromegaly patients with impaired 
glucose tolerance or diabetes mellitus at baseline, 
pasireotide LAR treatment was associated with worsening 
of glucose metabolism. This is an established feature 
of pasireotide treatment in preclinical and clinical 
studies of acromegaly (44, 45). We noted that both cases 
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developed marked elevations in HbA1c and this required 
multi-modal therapy and control was only achieved 
following the addition of insulin and GLP-1 agonists. The 
added burden of injectable and oral medical therapies 
due to diabetes mellitus has to be balanced against the 
excellent clinical, hormonal and tumoral responses 
that occurred with chronic pasireotide LAR. Given the 
resistant disease profile due to AIP mutations in these 
two patients, no other effective options were available 
that could produce both the complete hormonal control 
and impressive tumor shrinkage that were seen with 
pasireotide LAR.
In conclusion, pasireotide LAR treatment for up to 
11 years was associated with hormonal control and marked 
tumor shrinkage in the setting of octreotide/lanreotide-
resistant acromegaly due to germline AIP mutations. 
The magnitude and durability of the responses included 
tumoral and hormonal control for more than 18 months 
even after withdrawing pasireotide LAR in one patient. 
The profile of AIP-mutated somatotropinomas is one of 
early-onset and aggressive disease and challenging clinical 
management due to tumors that are poorly responsive to 
first-generation SSA, possibly due to low/absent SST2 and 
AIP expression. Pasireotide, with its affinity for multiple 
somatostatin receptors, could represent a tailored 
medical approach in some octreotide/lanreotide resistant 
acromegaly patients with AIP mutations.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This study was supported by a grant from the Fonds d’Investissement pour 
la Recherche Scientifique of the CHU de Liège and by a grant from the 
JABBS Foundation, UK.
References
 1 Caputo M, Ucciero A, Mele C, De Marchi L, Magnani C, Cena T, 
Marzullo P, Barone-Adesi F & Aimaretti G. Use of administrative 
health databases to estimate incidence and prevalence of 
acromegaly in Piedmont Region, Italy. Journal of Endocrinological 
Investigation 2018 [epub]. (https://doi.org/10.1007/s40618-018-
0928-7)
 2 Gruppetta M, Mercieca C & Vassallo J. Prevalence and incidence of 
pituitary adenomas: a population based study in Malta. Pituitary 
2013 16 545–553. (https://doi.org/10.1007/s11102-012-0454-0)
 3 Gatto F, Trifirò G, Lapi F, Cocchiara F, Campana C, Dell’Aquila C, 
Ferrajolo C, Arvigo M, Cricelli C, Giusti M, et al. Epidemiology of 
acromegaly in Italy: analysis from a large longitudinal primary care 
database. Endocrine 2018 61 533–541. (https://doi.org/10.1007/
s12020-018-1630-4)
 4 Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA 
& Beckers A. High prevalence of pituitary adenomas: a cross-
sectional study in the province of Liège, Belgium. Journal of Clinical 
Endocrinology and Metabolism 2006 91 4769–4775. (https://doi.
org/10.1210/jc.2006-1668)
 5 Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-
Fathallah M, Auriemma R, Diallo AM, Hulting AL, Ferone D, et al. 
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly 
Survey (LAS) database. Endocrine-Related Cancer 2017 24 505–518. 
(https://doi.org/10.1530/ERC-17-0253)
 6 Mantovani G, Lania AG & Spada A. GNAS imprinting and pituitary 
tumors. Molecular and Cellular Endocrinology 2010 326 15–18. 
(https://doi.org/10.1016/j.mce.2010.04.009)
 7 Rostomyan L, Daly AF & Beckers A. Pituitary tumors associated with 
multiple endocrine neoplasia syndromes. Encyclopedia of Endocrine 
Diseases 2019 1 642–647. (https://doi.org/10.1016/B978-0-12-
801238-3.66169-X)
 8 Daly AF & Beckers A. Familial isolated pituitary adenomas (FIPA) and 
mutations in the aryl hydrocarbon receptor interacting protein (AIP) 
gene. Endocrinology and Metabolism Clinics of North America 2015 44 
19–25. (https://doi.org/10.1016/j.ecl.2014.10.002)
 9 Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-
Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, et al. 
Clinical characteristics and therapeutic responses in patients with 
germ-line AIP mutations and pituitary adenomas: an international 
collaborative study. Journal of Clinical Endocrinology and Metabolism 
2010 95 E373–E383. (https://doi.org/10.1210/jc.2009-2556)
 10 Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, 
Tilley D, Ferrau F, Evanson J, Ellard S, Grossman AB, et al. Landscape 
of familial isolated and young-onset pituitary adenomas: prospective 
diagnosis in AIP mutation carriers. Journal of Clinical Endocrinology 
and Metabolism 2015 100 E1242–E1254. (https://doi.org/10.1210/
jc.2015-1869)
 11 Tuominen I, Heliövaara E, Raitila A, Rautiainen MR, Mehine M, 
Katainen R, Donner I, Aittomäki V, Lehtonen HJ, Ahlsten M, et al. 
AIP inactivation leads to pituitary tumorigenesis through defective 
Gαi-cAMP signaling. Oncogene 2015 34 1174–1184. (https://doi.
org/10.1038/onc.2014.50)
 12 Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, 
Igreja SC, Chapple JP, Jordan S, Lupp A, et al. Somatostatin analogs 
modulate AIP in somatotroph adenomas : the role of the ZAC1 
pathway. Journal of Clinical Endocrinology and Metabolism 2012 97 
1–10. (https://doi.org/10.1210/jc.2012-1111)
 13 Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, 
Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, 
Pagotto U, et al. Tumor ZAC1 expression is associated with 
the response to somatostatin analog therapy in patients with 
acromegaly. International Journal of Cancer 2009 125 2122–2126. 
(https://doi.org/10.1002/ijc.24602)
 14 Joshi K, Daly AF, Beckers A & Zacharin M. Resistant paediatric 
somatotropinomas due to AIP mutations: role of pegvisomant. 
Hormone Research in Paediatrics 2018 90 196–202. (https://doi.
org/10.1159/000488856)
 15 Ben-Shlomo A & Melmed S. Pasireotide – a somatostatin analog for 
the potential treatment of acromegaly, neuroendocrine tumors and 
Cushing’s disease. IDrugs 2007 10 885–895.
 16 Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F & Ferone D. 
Somatostatin receptor ligands in the treatment of acromegaly. 
Pituitary 2017 20 100–108. (https://doi.org/10.1007/s11102-017-
0791-0)
 17 Körner M, Waser B, Christ E, Beck J & Reubi JC. A critical evaluation 
of sst3 and sst5 immunohistochemistry in human pituitary 
adenomas. Neuroendocrinology 2018 106 116–127. (https://doi.
org/10.1159/000472563)
 18 Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, 
Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, 
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-19-0004
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/20/2019 10:20:12AM
via Universitaetsbibliothek Bern and Universitat Bern
A F Daly et al. Pasireotide in AIP-mutated 
acromegaly
376
PB–11
8:4
Tamburrano G, et al. Aryl hydrocarbon receptor-interacting protein 
gene mutations in familial isolated pituitary adenomas: analysis in 
73 families. Journal of Clinical Endocrinology and Metabolism 2007 92 
1891–1896. (https://doi.org/10.1210/jc.2006-2513)
 19 Salvatori R, Daly AF, Quinones-Hinojosa A, Thiry A & Beckers A. 
A clinically novel AIP mutation in a patient with a very large, 
apparently sporadic somatotrope adenoma. Endocrinology, Diabetes 
and Metabolism Case Reports 2014 2014 140048. (https://doi.
org/10.1530/EDM-14-0048)
 20 Schmid HA. Pasireotide (SOM230): development, mechanism of 
action and potential applications. Molecular and Cellular Endocrinology 
2008 286 69–74. (https://doi.org/10.1016/j.mce.2007.09.006)
 21 Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, 
Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, et al. Treatment 
of pituitary-dependent Cushing’s disease with the multireceptor 
ligand somatostatin analog pasireotide (SOM230): a multicenter, 
phase II trial. Journal of Clinical Endocrinology and Metabolism 2009 94 
115–122. (https://doi.org/10.1210/jc.2008-1008)
 22 Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, 
Buchelt A, Ho YY, Hu K, Farrall AJ, et al. Pasireotide (SOM230) 
demonstrates efficacy and safety in patients with acromegaly: 
a randomized, multicenter, phase II trial. Journal of Clinical 
Endocrinology and Metabolism 2010 95 2781–2789. (https://doi.
org/10.1210/jc.2009-2272)
 23 Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, 
Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, et al. 
Switching patients with acromegaly from octreotide to pasireotide 
improves biochemical control: crossover extension to a randomized, 
double-blind, Phase III study. BMC Endocrine Disorders 2016 16 16. 
(https://doi.org/10.1186/s12902-016-0096-8)
 24 Treppiedi D, Giardino E, Catalano R, Mangili F, Vercesi P, Sala E, 
Locatelli M, Arosio M, Spada A, Mantovani G, et al. Somatostatin 
analogs regulate tumor corticotrophs growth by reducing ERK1/2 
activity. Molecular and Cellular Endocrinology 2019 483 31–38. 
(https://doi.org/10.1016/j.mce.2018.12.022)
 25 Gatto F, Arvigo M, Amarù J, Campana C, Cocchiara F, Graziani G, 
Bruzzone E, Giusti M, Boschetti M & Ferone D. Cell specific 
interaction of pasireotide: review of preclinical studies in 
somatotroph and corticotroph pituitary cells. Pituitary 2019 22 
89–99. (https://doi.org/10.1007/s11102-018-0926-y)
 26 Villa C, Lagonigro MS, Magri F, Koziak M, Jaffrain-Rea ML, Brauner R, 
Bouligand J, Junier MP, Di F, Sainte-Rose C, et al. Hyperplasia-
adenoma sequence in pituitary tumorigenesis related to aryl 
hydrocarbon receptor interacting protein gene mutation. Endocrine-
Related Cancer 2011 18 347–356. (https://doi.org/10.1530/ERC-11-
0059)
 27 Yamamoto R, Robert Shima K, Igawa H, Kaikoi Y, Sasagawa Y, 
Hayashi Y, Inoshita N, Fukuoka H, Takahashi Y & Takamura T. 
Impact of preoperative pasireotide therapy on invasive octreotide-
resistant acromegaly. Endocrine Journal 2018 65 1061–1067. (https://
doi.org/10.1507/endocrj.EJ17-0487)
 28 Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun 
Fathallah M, Castinetti F, Devuyst F, Jaffrain Rea ML, Briet C, et al. 
T2-weighted MRI signal predicts hormone and tumor responses to 
somatostatin analogs in acromegaly. Endocrine-Related Cancer 2016 
23 871–881. (https://doi.org/10.1530/ERC-16-0356)
 29 Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, 
Rostomyan L, Defilles C, Angelini M, Oliva MA, et al. Somatostatin 
analogues increase AIP expression in somatotropinomas, irrespective 
of Gsp mutations. Endocrine-Related Cancer 2013 20 753–766. 
(https://doi.org/10.1530/ERC-12-0322)
 30 Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, 
Daly AF, Vanbellinghen JF, D’Innocenzo E, Barlier A, Giangaspero F, 
Esposito V, et al. Expression of aryl hydrocarbon receptor (AHR) and 
AHR-interacting protein in pituitary adenomas: pathological and 
clinical implications. Endocrine-Related Cancer 2009 16 1029–1043. 
(https://doi.org/10.1677/ERC-09-0094)
 31 Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, De Castro M, 
Takiya CM & Gadelha MR. AIP expression in sporadic 
somatotropinomas is a predictor of the response to octreotide LAR 
therapy independent of SSTR2 expression. Endocrine-Related Cancer 
2012 19 L25–L29. (https://doi.org/10.1530/ERC-12-0020)
 32 Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, 
Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM & 
Gadelha MR. Low aryl hydrocarbon receptor-interacting protein 
expression is a better marker of invasiveness in somatotropinomas 
than Ki-67 and p53. Neuroendocrinology 2011 94 39–48. (https://doi.
org/10.1159/000322787)
 33 Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, 
Erneux C, Florio T, Pagotto U & Stalla GK. Octreotide, a somatostatin 
analogue, mediates its antiproliferative action in pituitary tumor cells 
by altering phosphatidylinositol 3-kinase signaling and inducing 
Zac1 expression. Cancer Research 2006 66 1576–1582. (https://doi.
org/10.1158/0008-5472.CAN-05-1189)
 34 Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, 
Giampietro A, Mormando M, Clear AJ, Doglietto F, et al. Factors 
predicting pasireotide responsiveness in somatotroph pituitary 
adenomas resistant to first-generation somatostatin analogues: an 
immunohistochemical study. European Journal of Endocrinology 2016 
174 241–250. (https://doi.org/10.1530/EJE-15-0832)
 35 Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, 
Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross total 
resection or debulking of pituitary adenomas improves hormonal 
control of acromegaly by somatostatin analogs. European Journal of 
Endocrinology 2005 152 61–66. (https://doi.org/10.1530/eje.1.01824)
 36 Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-
Sanderson V, Rowlers S, Trainer PJ & Wass JA. Surgical debulking 
of pituitary macroadenomas causing acromegaly improves control 
by lanreotide. Clinical Endocrinology 2008 68 970–975. (https://doi.
org/10.1111/j.1365-2265.2007.03139.x)
 37 Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, 
Lecumberri B, Trivellin G, Salvatori R, Moraitis AG, et al. Clinical 
and genetic characterization of pituitary gigantism: an international 
collaborative study in 208 patients. Endocrine-Related Cancer 2015 22 
745–757. (https://doi.org/10.1530/ERC-15-0320)
 38 Beckers A, Petrossians P, Hanson J & Daly AF. The causes and 
consequences of pituitary gigantism. Nature Reviews Endocrinology 
2018 14 705–720. (https://doi.org/10.1038/s41574-018-0114-1)
 39 Mangupli R, Rostomyan L, Castermans E, Caberg JH, Camperos P, 
Krivoy J, Cuauro E, Bours V, Daly AF & Beckers A. Combined 
treatment with octreotide LAR and pegvisomant in patients with 
pituitary gigantism: clinical evaluation and genetic screening. 
Pituitary 2016 19 507–514. (https://doi.org/10.1007/s11102-016-
0732-3)
 40 Urbani C, Russo D, Raggi F, Lombardi M, Sardella C, Scattina I, 
Lupi I, Manetti L, Tomisti L, Marcocci C, et al. A novel germline 
mutation in the aryl hydrocarbon receptor-interacting protein (AIP) 
gene in an Italian family with gigantism. Journal of Endocrinological 
Investigation 2014 37 949–955. (https://doi.org/10.1007/s40618-014-
0123-4)
 41 Raitila A, Georgitsi M, Bonora E, Vargiolu M, Tuppurainen K, 
Makinen MJ, Vierimaa O, Salmela PI, Launonen V, Vahteristo P, 
et al. Aryl hydrocarbon receptor interacting protein mutations 
seem not to associate with familial non-medullary thyroid cancer. 
Journal of Endocrinological Investigation 2009 32 426–429. (https://doi.
org/10.1007/BF03346480)
 42 Matsuo K, Tang SH & Fagin JA. Allelotype of human thyroid tumors: 
loss of chromosome 11q13 sequences in follicular neoplasms. 
Molecular Endocrinology 1991 5 1873–1879. (https://doi.org/10.1210/
mend-5-12-1873)
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-19-0004
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/20/2019 10:20:12AM
via Universitaetsbibliothek Bern and Universitat Bern
A F Daly et al. Pasireotide in AIP-mutated 
acromegaly
3778:4
 43 Nord B, Larsson C, Wong FK, Wallin G, Teh BT & Zedenius J. 
Sporadic follicular thyroid tumors show loss of a 200-kb region in 
11q13 without evidence for mutations in the MEN1 gene. Genes, 
Chromosomes and Cancer 1999 26 35–39. (https://doi.org/10.1002/
(SICI)1098-2264(199909)26:1<35::AID-GCC5>3.0.CO;2-L)
 44 Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P,  
Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S &  
Vergès B. Management of hyperglycaemia in Cushing’s 
disease: experts’ proposals on the use of pasireotide. Diabetes 
and Metabolism 2013 39 34–41. (https://doi.org/10.1016/j.
diabet.2012.10.005)
 45 Tarasco E, Seebeck P, Pfundstein S, Daly AF, Eugster PJ, Harris AG, 
Grouzmann E, Lutz TA & Boyle CN. Effect of AP102, a subtype  
2 and 5 specific somatostatin analog, on glucose metabolism  
in rats. Endocrine 2017 58 124–133. (https://doi.org/10.1007/ 
s12020-017-1386-2)
Received in final form 27 February 2019
Accepted 8 March 2019
Accepted Preprint published online 8 March 2019
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-19-0004
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/20/2019 10:20:12AM
via Universitaetsbibliothek Bern and Universitat Bern
